A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
Terminated · Phase 1 · NCT06685718
Conditions: Non-Small Cell Lung Cancer, Lung Cancer, NSCLC, NSCLC (Non-small Cell Lung Carcinoma), EGFR Activating Mutation, EGFR Mutation-Related Tumors
At a glance
- Research payments reported, 2025
- $474,066
- U.S. investigators named
- 5
- Sites paid
- 5
- Planned or actual enrollment
- 33
About the trial
- Sponsor
- BeOne Medicines
- Tested
- BG-60366 (drug)
- Dates
- Started 2024-12-05; completion 2026-04-21
- Results posted
- Not yet
This is an open-label, multicenter, Phase 1a/1b clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of BG-60366, a highly potent, selective EGFR-mutation targeted Chimeric Degradation Activation Compound (CDAC). BG-60366 is designed to degrade mutant EGFR, which is a common cause for Non-Small Cell Lung Cancer (NSCLC). This study will evaluate how well BG-60366 works in participants with advanced or metastatic EGFR-mutant NSCLC. The study will be conducted in 2 parts: 1) Phase 1a Dose Escalation and Safety Expansion, and 2) Phase 1b Dose Expansion.
From ClinicalTrials.gov, last updated 2026-05-22. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Beone Medicines USA, Inc. reported $474,066 in research payments for this study in 2025 (24 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Erin L. Schenk, MD Medical Oncology · Aurora, CO
- Pasi Antero Janne, MD PHD Medical Oncology · Boston, MA
- Xiuning Le, M.D. Specialist · Boston, MA
- Ayse Ece Cali Daylan, MD Medical Oncology · Saint Louis, MO
- Helena Yu, MD Internal Medicine · New York, NY
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Ut MD Anderson Cancer Center $147,421
- Memorial Sloan Kettering Cancer Center $122,008
- University of Colorado Cancer Center $85,852
- Washington University $82,935
- Dana Farber Mass General Brigham Cancer Care Inc $35,850
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.